Med24
overweight-obesity 28. 10. 2026 • 2 min read • Europe PMC

Genetic axes of hand and shoulder soft-tissue disease and their divergent responses to adiposity and incretin therapy: a cross-biobank genomic and randomised trial study

Summary Background Hand and shoulder soft-tissue disorders cluster in people with obesity and diabetes, now widely treated with incretin receptor agonists. Whether these disorders share genetic causes, and whether pharmacological weight loss relieves or provokes them, is unknown. Methods We analysed genome-wide data...

MASH-riskin tunnistaminen: Tutkimus Ruotsista

This study investigated the genetic basis of hand and shoulder soft-tissue disorders and their responses to adiposity and incretin therapy. Analysis of genome-wide data from multiple biobanks revealed two distinct, heritable axes: a tenosynovial axis encompassing carpal tunnel syndrome, trigger finger, and de Quervain tenosynovitis, and a fibro-capsular axis including frozen shoulder, Dupuytren’s disease, and plantar fascial disorder. POSTN was identified within the fibro-capsular axis.

Sponsored content

Key Clinical Findings

Genetically elevated body mass index was associated with an increased risk of carpal tunnel syndrome and a decreased risk of Dupuytren’s disease. Incretin receptor agonists were linked to increased serious events within the fibro-capsular axis, specifically frozen shoulder and Dupuytren’s disease, but not the tenosynovial axis. The study identified distinct genetic pathways within each axis, with the tenosynovial axis influenced by obesity and extracellular matrix genes in tenocyte-like fibroblasts, and the fibro-capsular axis characterized by Wnt signalling and POSTN expression in lesional fibroblasts. Findings suggest these disorders represent distinct aetiological axes with opposing responses to adiposity and pharmacological weight reduction, highlighting frozen shoulder and Dupuytren’s disease as potential musculoskeletal safety outcomes for patients receiving incretin receptor agonists.

Original Scientific Source
Europe PMC
View Original Source
Medical Disclaimer All calculations, recommendations, and interpretations provided by this tool are for informational and educational purposes only. They do not substitute professional medical advice, diagnosis, or treatment. Always consult your physician regarding any health concerns.

Recommended Medical News

All news →
The interpretation of body-composition metrics in obesity
overweight-obesity

The interpretation of body-composition metrics in obesity

Modern obesity care is increasingly therapeutic, longitudinal, and outcome-oriented, yet clinical assessment often remains centered on total body weight and BMI. Although BMI remains useful for screening and population-level risk stratification, it cannot characterize the biological heterogeneity of obesity or the...

26. 10. 2026 Read article →
Efficacy and safety of orforglipron in adults with body mass index of 27 to less than 30 kg/m 2 and adiposity-related complications: A post hoc analysis of the ATTAIN-1 trial
overweight-obesity

Efficacy and safety of orforglipron in adults with body mass index of 27 to less than 30 kg/m 2 and adiposity-related complications: A post hoc analysis of the ATTAIN-1 trial

Background Orforglipron, an oral small-molecule glucagon-like peptide-1 receptor agonist, improved body weight and cardiometabolic parameters in the phase 3 ATTAIN-1 trial, but its efficacy and safety in adults with body mass index (BMI) of ≥27 to 2 and adiposity-related complications have not been characterized....

14. 10. 2026 Read article →
Advertisement